Combination therapy with savolitinib and osimertinib shows promising results in treating advanced NSCLC with EGFR mutations ...

Immunohistochemistry is the primary option, as long as the cases classified as 2+ or equivocal are re-evaluated by in situ hybridization. Mechanisms of EGFR upregulation are dependent on the ...

During a live event, Neal E. Ready, MD, and participants discussed use of PD-L1 status in non–small cell lung cancer and ...